ETNB 89bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ETNB

Price (delayed)

$18.96

Market cap

$1.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.64

Enterprise value

$1.06B

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is ...

Highlights
The equity has soared by 194% since the previous quarter
89bio's quick ratio has soared by 192% YoY and by 162% from the previous quarter
89bio's debt has increased by 27% YoY and by 20% QoQ
The company's net income fell by 4.4% YoY and by 3.2% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.89bio.com
Peers: OVID

Key stats

What are the main financial stats of ETNB
Market
Shares outstanding
72.87M
Market cap
$1.38B
Enterprise value
$1.06B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$101.28M
EBITDA
-$101.01M
Free cash flow
-$86.83M
Per share
EPS
-$2.64
Free cash flow per share
-$1.63
Book value per share
$8.54
Revenue per share
$0
TBVPS
$9.3
Balance sheet
Total assets
$494.32M
Total liabilities
$48.49M
Debt
$24.65M
Equity
$445.83M
Working capital
$469.62M
Liquidity
Debt to equity
0.06
Current ratio
20.56
Quick ratio
20.02
Net debt/EBITDA
3.23
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-40.5%
Return on equity
-50.7%
Return on invested capital
-85.3%
Return on capital employed
-21.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ETNB stock price

How has the 89bio stock price performed over time
Intraday
0.42%
1 week
7.18%
1 month
19.85%
1 year
467.66%
YTD
48.94%
QTD
24.49%

Financial performance

How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$105.67M
Net income
-$105.3M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 6% YoY and by 3.3% QoQ
The company's net income fell by 4.4% YoY and by 3.2% QoQ

Growth

What is 89bio's growth rate over time

Valuation

What is 89bio stock price valuation
P/E
N/A
P/B
2.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ETNB's EPS is up by 47% year-on-year and by 10% since the previous quarter
The equity has soared by 194% since the previous quarter
The stock's price to book (P/B) is 11% more than its last 4 quarters average of 2.0

Efficiency

How efficient is 89bio business performance
89bio's return on equity has increased by 39% QoQ and by 31% YoY
ETNB's return on assets is up by 35% year-on-year and by 32% since the previous quarter
The ROIC has grown by 12% from the previous quarter and by 6% YoY

Dividends

What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ETNB.

Financial health

How did 89bio financials performed over time
89bio's quick ratio has soared by 192% YoY and by 162% from the previous quarter
ETNB's current ratio has surged by 179% year-on-year and by 158% since the previous quarter
89bio's debt is 94% lower than its equity
The equity has soared by 194% since the previous quarter
ETNB's debt to equity has plunged by 68% YoY and by 57% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.